f12:dmem 1:1 Search Results


ham’s f12-dmem 1/1 supplemented with 10% nu-serum  (Weiss GmbH)
90
Weiss GmbH ham’s f12-dmem 1/1 supplemented with 10% nu-serum
Ham’s F12 Dmem 1/1 Supplemented With 10% Nu Serum, supplied by Weiss GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ham’s f12-dmem 1/1 supplemented with 10% nu-serum/product/Weiss GmbH
Average 90 stars, based on 1 article reviews
ham’s f12-dmem 1/1 supplemented with 10% nu-serum - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ham's f-12 dmem 1:1 containing 5% (v/v) delipidated fbs, 50 μ m sodium mevalonate, and 50 μ m mevastatin  (Enzo Biochem)
90
Enzo Biochem ham's f-12 dmem 1:1 containing 5% (v/v) delipidated fbs, 50 μ m sodium mevalonate, and 50 μ m mevastatin
Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by <t>mevastatin</t> treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).
Ham's F 12 Dmem 1:1 Containing 5% (V/V) Delipidated Fbs, 50 μ M Sodium Mevalonate, And 50 μ M Mevastatin, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ham's f-12 dmem 1:1 containing 5% (v/v) delipidated fbs, 50 μ m sodium mevalonate, and 50 μ m mevastatin/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
ham's f-12 dmem 1:1 containing 5% (v/v) delipidated fbs, 50 μ m sodium mevalonate, and 50 μ m mevastatin - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dulbecco's modified eagle's medium (dmem)  (Kyokuto Pharmaceutical Industrial Co Ltd)
90
Kyokuto Pharmaceutical Industrial Co Ltd dulbecco's modified eagle's medium (dmem)
Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by <t>mevastatin</t> treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).
Dulbecco's Modified Eagle's Medium (Dmem), supplied by Kyokuto Pharmaceutical Industrial Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dulbecco's modified eagle's medium (dmem)/product/Kyokuto Pharmaceutical Industrial Co Ltd
Average 90 stars, based on 1 article reviews
dulbecco's modified eagle's medium (dmem) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
f12 medium dmem 1:1  (VivaCell Biotechnology GmbH)
90
VivaCell Biotechnology GmbH f12 medium dmem 1:1
Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by <t>mevastatin</t> treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).
F12 Medium Dmem 1:1, supplied by VivaCell Biotechnology GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/f12 medium dmem 1:1/product/VivaCell Biotechnology GmbH
Average 90 stars, based on 1 article reviews
f12 medium dmem 1:1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ham’s f-12: dmem (1 : 1)  (Nissui Pharmaceutical)
90
Nissui Pharmaceutical ham’s f-12: dmem (1 : 1)
Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by <t>mevastatin</t> treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).
Ham’s F 12: Dmem (1 : 1), supplied by Nissui Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ham’s f-12: dmem (1 : 1)/product/Nissui Pharmaceutical
Average 90 stars, based on 1 article reviews
ham’s f-12: dmem (1 : 1) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by mevastatin treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).

Journal: The Journal of Biological Chemistry

Article Title: Mechanism of Folding and Activation of Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P) *

doi: 10.1074/jbc.M115.677757

Figure Lengend Snippet: Characterization of the activity of the prodomain deletion mutants. A, SREBP-2 processing by SKI-1/S1P mutants. SRD12B cells were transfected with the indicated SKI-1/S1P constructs. After 32 h, the SREBP-2 pathway was induced by mevastatin treatment for 18 h, whereas control cells were treated with DMSO. After treatment, total RNA was extracted to analyze HGMCS1 gene induction by quantitative RT-PCR. The results were analyzed by the ΔΔCT method, and the data were normalized against hydroxymethylbilane synthase gene expression. Gene expression is represented as fold induction above levels for control treatment (pIR-HA DMSO) (mean ± S.D.; n = 3). B, expression of SKI-1/S1P variants in A was assessed by Western blot as in Fig. 1B. C and D, LASV and LCMV GPC processing by the SKI-1/S1P mutants. SRD12B cell were co-transfected with either LASV GPC (C) or LCMV GPC (D) and the indicated SKI-1/S1P variants. At 48 h post-transfection, the cell lysates were analyzed by Western blot to assess GPC processing. SKI-1/S1P expression was detected with anti-V5 antibody and tubulin (Tub) detected as loading control. Tubulin, the precursor GPC, mature GP2, and maturation forms of SKI-1/S1P (forms A, B, and C) are indicated. E, schematic of the SKI-1/S1P sensor bearing the cleavage motif of LASV GPC. The signal peptide (SP), the GLuc reporter, the LASV GPC-derived cleavage motif, and the SKI-1/S1P-derived stump region are indicated. F, processing of the SKI-1/S1P sensor by SKI-1/S1P mutants. SRD12B cells were co-transfected with the SKI-1/S1P sensor (SS-LASV) and the indicated SKI-1/S1P variants. At 48 h post-transfection, cell lysates and supernatants were collected and analyzed by Western blot using an anti-GLuc antibody (bottom). Cleaved sensor (cGLuc) and the uncleaved precursor (pGLuc) are indicated. Conditioned media were analyzed for GLuc activity by addition of coelenterazine substrate. The data are shown as relative light units (RLU) (means ± S.D.; n = 3).

Article Snippet: Drug Treatments Induction of genes regulated by SREBP2 was triggered by treatment with Ham's F-12 DMEM 1:1 containing 5% (v/v) delipidated FBS, 50 μ m sodium mevalonate, and 50 μ m mevastatin (Enzo Lifescience) for 18 h, as reported previously ( 20 ).

Techniques: Activity Assay, Transfection, Construct, Quantitative RT-PCR, Expressing, Western Blot, Derivative Assay